Michael Okunewitch

Stock Analyst at Maxim Group

(0)
# 5070
Out of 5,333 analysts
25
Total ratings
15.00%
Success rate
-38.22%
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
RADX Radiopharm Theranostics
Initiates Coverage On: Buy
12
3.82 214.14% 1 May 1, 2025
CMMB Chemomab Therapeutics
Maintains: Strong Buy
4 7
1.21 478.51% 2 Feb 20, 2025
MYNZ Mainz Biomed
Initiates Coverage On: Buy
14
2.59 440.54% 1 Feb 14, 2025
LCTX Lineage Cell Therapeutics
Maintains: Buy
5 3
0.45 566.67% 1 Jan 10, 2025
CTOR Citius Oncology
Initiates Coverage On: Buy
3
0.85 252.94% 1 Nov 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
4
0.69 479.71% 1 Oct 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
12
0.84 1328.57% 1 Sep 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
15 6
1.49 302.68% 2 Aug 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
3 12
1.06 1032.08% 2 Mar 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
2
n/a n/a 1 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
24
1.22 1867.21% 1 Oct 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.11 440.54% 1 Sep 21, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
108 18
3.32 442.17% 3 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
225
n/a n/a 1 Apr 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
17.71 41.16% 1 Dec 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.84 226.09% 1 Sep 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
160
7.32 2085.79% 1 Mar 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
120
n/a n/a 1 Feb 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
1.4 1685.71% 1 Nov 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
100
0.67 14825.37% 1 Nov 30, 2021